Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05595070
Other study ID # 2022-13654
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date April 1, 2022
Est. completion date December 31, 2023

Study information

Verified date October 2022
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Haematopoietic stem cell transplantation (HSCT) is a potentially lifesaving treatment option for various diseases. It involves infusion of stem cells after a conditioning regimen of chemotherapy with or without total body irradiation. There is a concern that HSCT and accompanying treatments may increase the risk for oral complications. Nevertheless, longitudinal studies measuring oral health before and after HSCT are scarce. Hence, we formulated the following research question: In adult HSCT recipients, do oral health parameters change from baseline (pre-HSCT) to 3 - 24 months post-HSCT, and is the type of conditioning regimen associated with this change in oral health parameters? To answer this research question, we will use data from the electronic health records of the Radboudumc (Epic and Dentium). We will include at least seventy-five adult patients who are examined both before and after HSCT at the department of Dentistry (Radboudumc) as part of an oral care program. The following oral health parameters were assessed: status praesens, pocket probing depth, bleeding on probing, periodontal epithelial surface area, periodontal inflamed surface area, xerostomia, unstimulated and stimulated salivary flow rate and pH, cariesactivity, oral chronic Graft-versus-Host Disease and dental treatments. Patients were subjected to different regimens in preparation for HSCT, namely myeloablative, reduced intensity or non-myeloablative conditioning. To estimate the association between conditioning regimen and the change in oral health parameters, we will use mixed effects models with random effects, adjusted for potential confounders. Results will be reported as regression coefficients with corresponding 95% confidence intervals.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 200
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Allogeneic HSCT between 2013 and 2021 at Radboudumc - Oral focal screening before HSCT, and at least one oral examination after HSCT performed at Department of Dentistry, Radboudumc - Informed consent Exclusion Criteria: - Not meeting the inclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Haematopoietic stem cell transplantation
Haematopoietic stem cell transplantation (HSCT) is widely used in the treatment of malignant and non-malignant conditions to reconstitute the immune system secondary to cytotoxic conditioning regimens. These regimens, consisting of chemotherapy with or without total body irradiation, cause severe immunosuppression prior to, during and after HSCT. Immune reconstitution takes place by infusion of stem cells either harvested from the patient (autologous HSCT) or from a donor (allogeneic HSCT).

Locations

Country Name City State
Netherlands Radboudumc Nijmegen

Sponsors (1)

Lead Sponsor Collaborator
Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of teeth Number of teeth (range 0 - 32) Change from baseline (pre-HSCT) up to 24 months after HSCT
Primary Number of restorations Total number of restored tooth surfaces Change from baseline (pre-HSCT) up to 24 months after HSCT
Primary Pocket probing depth Pocket probing depth at 6 sites per tooth in millimetres Change from baseline (pre-HSCT) up to 24 months after HSCT
Primary Bleeding on probing Profound bleeding on probing at 6 sites per tooth as yes or no Change from baseline (pre-HSCT) up to 24 months after HSCT
Primary Unstimulated and chewing stimulated salivary flow rate Whole mouth saliva, measured in mL/min Change from baseline (pre-HSCT) up to 24 months after HSCT
Primary Unstimulated and chewing stimulated salivary pH Whole mouth saliva, measured with pH strips Change from baseline (pre-HSCT) up to 24 months after HSCT
Secondary Periodontal Epithelial Surface Area The root surface area in square millimetres affected by attachment loss Change from baseline (pre-HSCT) up to 24 months after HSCT
Secondary Periodontal Inflamed Surface Area The root surface area in square millimetres affected by attachment loss and inflamed periodontal tissue Change from baseline (pre-HSCT) up to 24 months after HSCT
Secondary Xerostomia Subjective oral dryness measured by Xerostomia Inventory questionnaire Change from baseline (pre-HSCT) up to 24 months after HSCT
Secondary Cariesactivity Likelihood for development of new caries lesions based on notes recorded by the dentist Up to 24 months after HSCT
Secondary Oral chronic Graft-versus-Host Disease Assessed with National Institute of Health Oral Mucosal Score (range 0 - 15), higher score means more severe oral manifestations of oral chronic Graft-versus-Host Disease Up to 24 months after HSCT
Secondary Extractions Total number of removed teeth (range 0 - 32) Between baseline (pre-HSCT) and up to 24 months after HSCT
Secondary Periodontal care Number of participants per type of periodontal care, categorised in sub- and supragingival cleaning, subgingival cleaning, no cleaning Between baseline (pre-HSCT) and up to 24 months after HSCT
Secondary Preventive measures Number of participants per type of preventive measure as fluoride varnish and oral hygiene instructions Between baseline (pre-HSCT) and up to 24 months after HSCT
See also
  Status Clinical Trial Phase
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Recruiting NCT06080490 - Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Recruiting NCT03871296 - DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
Not yet recruiting NCT06022445 - Prospective Validation of CARPET Prognostic Model for Septic Shock After Allo-HSCT
Recruiting NCT04502628 - Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT N/A
Recruiting NCT03793517 - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT Phase 2/Phase 3
Completed NCT03454568 - The Patients' Experience After Stem Cell Transplant
Recruiting NCT05466201 - The Use of Eltrombopag Post HSCT in BMFS Phase 2/Phase 3
Not yet recruiting NCT04080622 - Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation. Phase 3
Recruiting NCT05523336 - Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation
Completed NCT03355235 - Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
Completed NCT04888286 - DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
Not yet recruiting NCT05421416 - Loratadine for the Prevention of G-CSF-related Bone Pain Phase 2
Recruiting NCT04167683 - Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
Active, not recruiting NCT03967665 - Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution Phase 3
Withdrawn NCT05104268 - Study of a New Medical Device for Oral Mucositis Early Phase 1
Recruiting NCT04623424 - Intestinal Microbiota in Stem Cell Transplant Transplant Admission
Active, not recruiting NCT04669210 - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Phase 2
Completed NCT03489551 - Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients Phase 4